News

ASGN's Q3 2024 Performance Highlights Significant Growth

ASGN's Q3 2024 Performance Highlights Significant Growth

ASGN Incorporated Reports Financial Results for Q3 2024

ASGN Incorporated (NYSE: ASGN), recognized for its robust IT services and solutions across both commercial and government sectors, has recently unveiled its financial performance for the quarter ending September 30, 2024.

Quarterly Highlights

The company demonstrated a strong performance, recording revenues of $1.031 billion. Additionally, net income recorded was $47.5 million, showcasing the company's continued growth trajectory in the IT consulting space.

Key Financial Metrics

  • Adjusted EBITDA was $116.9 million, which translates to 11.3% of revenues.
  • Operating cash flows reached an impressive $135.8 million, with free cash flow standing at $127.9 million.
  • ASGN also strategically repurchased around 1.0 million shares, totaling $95.6 million in value.

Breakdown of IT Consulting Revenues

The structure of ASGN's revenue reveals that approximately 57.9% originates from IT consulting services. In the commercial segment alone, new bookings over the trailing twelve months stood at $1.2 billion, yielding a favorable book-to-bill ratio of 1.1:1.

On the federal government side, new contract awards for the same period were reported at $1.1 billion, with a book-to-bill ratio of 0.9:1.

Management's Perspective

Ted Hanson, the Chief Executive Officer of ASGN, commented on the results for Q3 2024, emphasizing the stability of market demand. He noted, "Our results reflect a shift towards high-value IT consulting work, reaching nearly 60% of total revenues. This shift is crucial as clients prioritize advancing their IT strategies to maintain competitiveness."

Insights into Financial Summary

For Q3, total IT consulting revenue was registered at $597.2 million, compared to $608.6 million in Q3 2023. The breakdown indicated that revenue from the commercial segment was approximately $285.0 million, indicating a year-over-year growth of 3.9%.

Despite an overall decline in some sectors, the Technology, Media, and Telecom (TMT) vertical exhibited double-digit growth due to strong demand. The Federal Government segment, yielding $312.2 million, showed slight reductions compared to previous figures.

Future Financial Projections

Moving forward, ASGN anticipates maintaining its strategic positions and servicing the evolving needs of its clients. They have outlined their estimates for the fourth quarter of 2024, remaining optimistic about remaining steady without market deterioration.

Fourth Quarter Expectations

The company projects revenues to fall between $990.0 million and $1.010 billion, reflecting cautious optimism while adhering to the financial trends established in the previous quarters.

Capital Allocation Strategy

ASGN has positioned itself for continued financial health with cash and cash equivalents standing at $166.6 million, and full availability under a $500.0 million revolving credit facility. This gave them the flexibility to repurchase shares amid market fluctuations.

Frequently Asked Questions

What are the main financial highlights of ASGN for Q3 2024?

ASGN reported revenues of $1.031 billion, a net income of $47.5 million, and an adjusted EBITDA of $116.9 million.

How much did ASGN spend on share repurchases?

In Q3 2024, ASGN repurchased approximately 1.0 million shares for $95.6 million.

What segments contributed to ASGN's total revenues?

IT consulting revenues accounted for 57.9% of total revenues, with significant contributions from both commercial and federal government segments.

What outlook does ASGN provide for Q4 2024?

ASGN expects revenues to range from $990 million to $1.010 billion, assuming no market deteriorations.

How does ASGN plan to allocate its cash reserves?

ASGN aims to utilize its cash reserves for strategic opportunities, further strengthening its market position and financial health.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

SKK Holdings Limited Announces Pricing for Share IPO Offering

Updated Category News Views 65

SKK Holdings Limited Announces Share Pricing for IPO SKK Holdings Limited (“SKK” or the “Company”) (Nasdaq: SKK), a specialized civil engineering service provider in subsurface utility works, has proudly announced the pricing of its initial public offering. The Company will offer 2,500,000 ordinary shares at a public offering price of $4.00 per share, yielding...

Continue Reading
Antelope Enterprise: Financial Performance Insights for 2024

Updated Category News Views 149

Antelope Enterprise Holdings Limited (NASDAQ: AEHL) hit the financial report stage hard back in mid-2024, flaunting numbers that tell quite the tale of both triumphs and tribulations. This company was hustling across two growing fronts: the fast-paced world of livestreaming ecommerce and the burgeoning energy sector down in Texas. Their half-year performance review...

Continue Reading
Olivier Falut Steps Into CFO Role at EUROAPI to Drive Growth

Updated Category News Views 344

Olivier Falut Joins EUROAPI as the New Chief Financial Officer EUROAPI is excited to announce the appointment of Olivier Falut as its new Chief Financial Officer, effective immediately. Olivier will be an integral member of the Executive Committee, succeeding Evelyne Nguyen. Evelyne will ensure continuity and a smooth transition within the company through her support...

Continue Reading
OPEXUS and Casepoint Join Forces for Growth and Innovation

Updated Category News Views 261

OPEXUS and Casepoint Unite for Strategic Growth In a significant development in the technology sector, OPEXUS, a frontrunner in government process management software, and Casepoint, an innovator in data discovery technology, have announced their merger. This significant move comes along with a majority investment from Thoma Bravo, a renowned software investment firm...

Continue Reading
MeiraGTx Holdings: An In-Depth Look at Future Potential

Updated Category News Views 69

MeiraGTx Holdings plc (NASDAQ:MGTX) was a clinical-stage gene therapy firm making waves back in 2024. The company announced a pivotal financial move, securing $50 million through equity financing at $4 per share, largely thanks to a $30 million investment from Sanofi (NYSE:SNY). While this funding boosted MGTX’s war chest, traders were already whispering about the heavy...

Continue Reading